Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.

Invest New Drugs · 2017 · PMC5418321 · PMID 28299514

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

We analyzed CXCR4 expression in CTCs by treatment arm, and Kaplan-Meier curves showed separation in PFS between treatment arms through the 4-month course of therapy, which did not reach statistical significance, for ≥6 CTCs or ≥7% CXCR4 + CTCs (Fig. 2a , b).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.